To establish the clinical response to srRNA vaccination, Phase II trials are ongoing in NSCLC (SLATE-KRAS) and metastatic colorectal cancer (GRANITE) in combination with ICB (NCT06253520, NCT05141721) [264]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.